We Did The Math XPH Can Go To $53

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the SPDR S&P Pharmaceuticals ETF (XPH), we found that the implied analyst target price for the ETF based upon its underlying holdings is $53.20 per unit.

START SLIDESHOW:
10 ETFs With Most Upside To Analyst Targets »

With XPH trading at a recent price near $44.44 per unit, that means that analysts see 19.71% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of XPH's underlying holdings with notable upside to their analyst target prices are Aclaris Therapeutics Inc ( ACRS), Theravance Biopharma, Inc. ( TBPH), and Jazz Pharmaceuticals plc ( JAZZ). Although ACRS has traded at a recent price of $24.19/share, the average analyst target is 90.16% higher at $46.00/share. Similarly, TBPH has 43.92% upside from the recent share price of $27.33 if the average analyst target price of $39.33/share is reached, and analysts on average are expecting JAZZ to reach a target price of $177.39/share, which is 29.73% above the recent price of $136.74. Below is a twelve month price history chart comparing the stock performance of ACRS, TBPH, and JAZZ:

ACRS, TBPH, and JAZZ Relative Performance Chart

Combined, ACRS, TBPH, and JAZZ represent 5.25% of the SPDR S&P Pharmaceuticals ETF. Below is a summary table of the current analyst target prices discussed above:

Name Symbol Recent Price Avg. Analyst 12-Mo. Target % Upside to Target
SPDR S&P Pharmaceuticals ETF XPH $44.44 $53.20 19.71%
Aclaris Therapeutics Inc ACRS $24.19 $46.00 90.16%
Theravance Biopharma, Inc. TBPH $27.33 $39.33 43.92%
Jazz Pharmaceuticals plc JAZZ $136.74 $177.39 29.73%

Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research.

The average analyst target price data upon which this article was based, is courtesy of data provided by Zacks Investment Research via Quandl.com.
Get the latest Zacks research report on ACRS — FREE
Get the latest Zacks research report on TBPH — FREE
Get the latest Zacks research report on JAZZ — FREE

More from Stocks

Markets Look Confused After Latest Beating

Markets Look Confused After Latest Beating

General Electric Expulsion From Dow Symbolizes Unsettled Week in Markets

General Electric Expulsion From Dow Symbolizes Unsettled Week in Markets

How Small-Cap Stocks Can Protect Your Portfolio From a Trade War

How Small-Cap Stocks Can Protect Your Portfolio From a Trade War

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

3 Great Stock Market Sectors Millennials Should Invest In

3 Great Stock Market Sectors Millennials Should Invest In